4basebio PLC (AIM:4BB)
530.00
0.00 (0.00%)
Nov 4, 2026, 8:00 AM GMT
4basebio Revenue
4basebio had revenue of 262.00K GBP in the half year ending June 30, 2026, a decrease of -20.12%. This brings the company's total for the last twelve months to 781.00K, down -56.10% year-over-year. In the year 2025, 4basebio had annual revenue of 1.69M with 81.46% growth. That makes 4basebio the 43,546th largest company in the world by revenue and 870th in the United Kingdom.
Revenue (ttm)
781.00K
Revenue Growth
-56.10%
P/S Ratio
105.45
Revenue / Employee
5.58K
Employees
140
Market Cap
82.35M
Revenue by Geography
- Europe 960.00K 56.7%
- USA 701.00K 41.4%
- Rest of World 32.00K 1.9%
Fiscal year ended Dec 31, 2025 See the full 4basebio breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.69M | 760.00K | 81.46% |
| Dec 31, 2024 | 933.00K | 427.00K | 84.39% |
| Dec 31, 2023 | 506.00K | 238.00K | 88.81% |
| Dec 31, 2022 | 268.00K | -70.00K | -20.71% |
| Dec 31, 2021 | 338.00K | -124.00K | -26.84% |
| Dec 31, 2020 | 462.00K | 260.00K | 128.71% |
| Dec 31, 2019 | 202.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bioventix | 12.97M |
| IXICO | 7.28M |
| Scancell Holdings | 4.71M |
| Ondine Biomedical | 1.53M |
| Faron Pharmaceuticals Oy | 1.14M |
| Arecor Therapeutics | 890.00K |
| Avacta Group | 113.00K |
| ImmuPharma | -69.96K |
4basebio News
- 14 days ago - 4basebio Plc - Result of Retail Offer - Finanz Nachrichten
- 15 days ago - 4basebio Plc - Posting of Circular and Notice of General Meeting - Finanz Nachrichten
- 20 days ago - 4basebio Plc - Proposed Retail Offer - Finanz Nachrichten
- 20 days ago - 4basebio Plc - Results of Capital Raise - Finanz Nachrichten
- 20 days ago - 4basebio Plc - Proposed Capital Raise of New Ordinary Shares to raise not less than £15 million - Finanz Nachrichten
- 1 month ago - 4basebio Plc - 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine - Finanz Nachrichten
- 2 months ago - 4basebio & Genezen Expand Collaboration For Viral Vector Manufacturing; Stock Up - Nasdaq
- 2 months ago - 4basebio Plc - 4basebio Enters into Strategic Collaboration and Marketing Agreement with Genezen to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing - Finanz Nachrichten